Acorda’s Phase iii- inhaled levodopa as rescue for “off ” times is promising! By Dr. De Leon

IMG_0617Fresh off the press-  I just had a great conversation with Dr. Harald Murk, senior Medical Director from Acorda Therapeutics Inc. regarding a new promising drug. This drug consists of an inhaled form of levodopa. The information on phase 2b was presented recently at the MDS conference in San Diego and was met with great enthusiasm as it offers a brand new venue of  introducing the drug for quick action that bypasses the gut, therefore eliminating Gi side effects. Plus gives a possible new armamentarium to use in the treatment of wearing off as well as for those who might suffer severe constipation or malabsorption leading to fluctuations in dose.

Thus far the trials have been well tolerated. My only concern is the affect this aerolized compound will have on  the lungs.

Me: do you require lung function testing prior to giving medication?

Dr. Murck: we don’t know what final requirements will be, at this point we have not seen any evidence to suggest diminished lung capacity although study still ongoing and pulmonologists are involved in the study to follow lung outcome.

Me: any side effects related to lung issues noticed thus far such as prolonged cough, bleed, or asthma?

Dr. Murck: occasionally people will have a cough when they inhale the product for the first time but this effect lasts a few seconds at most and is not recurrent.

Me: what are the doses available for study?

Dr. Murck: looking at a 35 mg and 50 mg and after a number of weeks patients will be unblended and ask to continue for another 3 months- essentially a three prong study

Me: how do you see this drug being used?

Dr. Murck : as a rescue drug 3-4 x a day

Me : are there still sites looking to recruit?

Dr. Murck: see list,

Gil

Ramon

Parkinson’s Disease Treatment Center of SW Florida

4235 Kings Highway, Suite 102

Port Charlotte

FL

Goldstein

Mark

JEM Research Institute

130 JFK Dr, Suite 203

Atlantis

FL

Goodman

Ira

Compass Research, LLC

100 West Gore St. Suite 202

Orlando

FL

Grainger

William

Neurological Physicians of Arizona

726 N. Greenfield  Rd. Suite 110

Gilbert

AZ

Hauser

Robert

University of South Florida – Parkinson’s Disease and Movement Disorders Center

4001 E. Fletcher Avenue, Suite 620

Tampa

FL

Isaacson

Stuart

Parkinson’s Disease and Movement Disorders Center of Boca Raton

951 NW 13th Street, Bldg.5E

Boca Raton

FL

Mehta

Shyamal

Mayo Clinic

13400 East Shea Blvd

Scottsdale

AZ

Oguh

Odinachi

University of Florida Health Science Center Jacksonville

580 West 8th St., Tower 1, 7th FL Suite 714

Jacksonville

FL

Shill

Holly

Banner Sun Health Research Institute

10515 W. Santa Fe Dr.

Sun City

AZ

I also know that Dr. Ondo at UT Houston is conducting this study as well.

Thank you Dr. Murck for your time!

We are still looking for volunteers especially women and minorities – if you know of someone who might be interested or yourself are interested in participating call these site above for further information.

Sources:

https://www.michaeljfox.org/mobile/news-detail.php?research-recap-from-movement-disorders-society-congress&utm_source=social&utm_medium=twitter&utm_content=researchnews&utm_campaign=MDSCongress&s_

src=MJFFtw&s_subsrc=MDSCongress&et_cid=273151&et_rid=61675349&et_lid=IPMDS+Congress+-+Read+More

Advertisements

Categories: parkinson's disease, Parkinson's Health, parkinsons treatments, research in parkinson's diseaseTags: , , ,

1 Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s